VTVT vTv Therapeutics Inc
Price (delayed)
$16.98
Market cap
$54.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.17
Enterprise value
$12.8M
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment
Highlights
VTVT's debt has dropped by 75% year-on-year and by 17% since the previous quarter
The company's EPS has surged by 58% YoY and by 36% QoQ
VTVT's equity has soared by 159% year-on-year but it is down by 9% since the previous quarter
Key stats
What are the main financial stats of VTVT
Market
Valuations
Earnings
Shares outstanding
3.19M
Market cap
$54.16M
Enterprise value
$12.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.41
Price to sales (P/S)
51.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.8
Revenue
$1M
Gross profit
$1M
Operating income
-$23.63M
Net income
-$18.31M
EBIT
-$18.2M
EBITDA
-$18.11M
Free cash flow
-$23.4M
Per share
Balance sheet
Liquidity
EPS
-$4.17
EPS diluted
-$4.17
Free cash flow per share
-$7.77
Book value per share
$4.99
Revenue per share
$0.33
TBVPS
$14.34
Total assets
$43.16M
Total liabilities
$25.25M
Debt
$213,000
Equity
$15.01M
Working capital
$36.53M
Debt to equity
0.01
Current ratio
6.69
Quick ratio
6.51
Net debt/EBITDA
2.28
Margins
Efficiency
Dividend
EBITDA margin
-1,810.9%
Gross margin
100%
Net margin
-1,830.6%
Operating margin
-2,362.9%
Return on assets
-47.3%
Return on equity
-265.3%
Return on invested capital
N/A
Return on capital employed
-49.5%
Return on sales
-1,819.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTVT stock price
How has the vTv Therapeutics stock price performed over time
Intraday
8.02%
1 week
15.04%
1 month
15.67%
1 year
98.83%
YTD
22.97%
QTD
22.97%
Financial performance
How have vTv Therapeutics's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$23.63M
Net income
-$18.31M
Gross margin
100%
Net margin
-1,830.6%
The operating margin has soared by 99% YoY but it has contracted by 6% from the previous quarter
VTVT's net margin has surged by 99% year-on-year and by 9% since the previous quarter
The net income is up by 15% year-on-year and by 9% since the previous quarter
VTVT's operating income is up by 8% YoY but it is down by 6% QoQ
Growth
What is vTv Therapeutics's growth rate over time
Valuation
What is vTv Therapeutics stock price valuation
P/E
N/A
P/B
3.41
P/S
51.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.8
The company's EPS has surged by 58% YoY and by 36% QoQ
VTVT's equity has soared by 159% year-on-year but it is down by 9% since the previous quarter
The P/S is 97% lower than the 5-year quarterly average of 1758.1
Efficiency
How efficient is vTv Therapeutics business performance
The company's return on sales has surged by 99% YoY and by 9% QoQ
vTv Therapeutics's return on assets has increased by 45% YoY and by 26% QoQ
Dividends
What is VTVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTVT.
Financial health
How did vTv Therapeutics financials performed over time
VTVT's total assets is 71% greater than its total liabilities
VTVT's total assets has soared by 189% year-on-year but it is down by 7% since the previous quarter
The total liabilities has contracted by 14% YoY and by 3% from the previous quarter
VTVT's debt is 99% smaller than its equity
VTVT's equity has soared by 159% year-on-year but it is down by 9% since the previous quarter
The debt to equity has soared by 133% year-on-year but it has dropped by 50% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.